144 related articles for article (PubMed ID: 16490840)
21. Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.
Endemann DH; Touyz RM; Iglarz M; Savoia C; Schiffrin EL
Hypertension; 2004 Jun; 43(6):1252-7. PubMed ID: 15117913
[TBL] [Abstract][Full Text] [Related]
22. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
Lainscak M; Pelliccia F; Rosano G; Vitale C; Schiariti M; Greco C; Speziale G; Gaudio C
Int J Cardiol; 2015 Dec; 200():25-9. PubMed ID: 26404748
[TBL] [Abstract][Full Text] [Related]
23. Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralocorticoid receptor antagonist.
Takeda Y
Hypertens Res; 2004 Nov; 27(11):781-9. PubMed ID: 15824460
[TBL] [Abstract][Full Text] [Related]
24. Long-term mineralocorticoid receptor blockade reduces fibrosis and improves cardiac performance and coronary hemodynamics in elderly SHR.
Susic D; Varagic J; Ahn J; Matavelli L; Frohlich ED
Am J Physiol Heart Circ Physiol; 2007 Jan; 292(1):H175-9. PubMed ID: 16905598
[TBL] [Abstract][Full Text] [Related]
25. Aldosterone target organ protection by eplerenone.
Rudolph AE; Rocha R; McMahon EG
Mol Cell Endocrinol; 2004 Mar; 217(1-2):229-38. PubMed ID: 15134822
[TBL] [Abstract][Full Text] [Related]
26. Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.
Takeda Y; Zhu A; Yoneda T; Usukura M; Takata H; Yamagishi M
Am J Hypertens; 2007 Oct; 20(10):1119-24. PubMed ID: 17903697
[TBL] [Abstract][Full Text] [Related]
27. Eplerenone, a selective aldosterone blocker, improves diastolic function in aged rats with small-to-moderate myocardial infarction.
Masson S; Staszewsky L; Annoni G; Carlo E; Arosio B; Bai A; Calabresi C; Martinoli E; Salio M; Fiordaliso F; Scanziani E; Rudolph AE; Latini R
J Card Fail; 2004 Oct; 10(5):433-41. PubMed ID: 15470655
[TBL] [Abstract][Full Text] [Related]
28. Effects of aldosterone and spironolactone on the isolated perfused rat heart.
Moreau D; Chardigny JM; Rochette L
Pharmacology; 1996 Jul; 53(1):28-36. PubMed ID: 8875599
[TBL] [Abstract][Full Text] [Related]
29. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Pitt B; Remme W; Zannad F; Neaton J; Martinez F; Roniker B; Bittman R; Hurley S; Kleiman J; Gatlin M;
N Engl J Med; 2003 Apr; 348(14):1309-21. PubMed ID: 12668699
[TBL] [Abstract][Full Text] [Related]
30. Blocking aldosterone in heart failure.
Shafiq MM; Miller AB
Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):379-85. PubMed ID: 19661156
[TBL] [Abstract][Full Text] [Related]
31. Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading.
Martinez DV; Rocha R; Matsumura M; Oestreicher E; Ochoa-Maya M; Roubsanthisuk W; Williams GH; Adler GK
Hypertension; 2002 Feb; 39(2 Pt 2):614-8. PubMed ID: 11882618
[TBL] [Abstract][Full Text] [Related]
32. Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts.
Noda K; Kobara M; Hamada J; Yoshifuji Y; Shiraishi T; Tanaka T; Wang J; Toba H; Nakata T
J Cardiovasc Pharmacol; 2012 Aug; 60(2):140-9. PubMed ID: 22549451
[TBL] [Abstract][Full Text] [Related]
33. Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in post-infarct rat hearts.
Takeda M; Tatsumi T; Matsunaga S; Hayashi H; Kimata M; Honsho S; Nishikawa S; Mano A; Shiraishi J; Yamada H; Takahashi T; Matoba S; Kobara M; Matsubara H
Hypertens Res; 2007 May; 30(5):427-37. PubMed ID: 17587755
[TBL] [Abstract][Full Text] [Related]
34. Eplerenone attenuates myocardial fibrosis in the angiotensin II-induced hypertensive mouse: involvement of tenascin-C induced by aldosterone-mediated inflammation.
Nishioka T; Suzuki M; Onishi K; Takakura N; Inada H; Yoshida T; Hiroe M; Imanaka-Yoshida K
J Cardiovasc Pharmacol; 2007 May; 49(5):261-8. PubMed ID: 17513943
[TBL] [Abstract][Full Text] [Related]
35. Rapid effects of aldosterone and spironolactone in the isolated working rat heart.
Barbato JC; Mulrow PJ; Shapiro JI; Franco-Saenz R
Hypertension; 2002 Aug; 40(2):130-5. PubMed ID: 12154102
[TBL] [Abstract][Full Text] [Related]
36. Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor.
Rogerson FM; Yao Y; Smith BJ; Fuller PJ
Clin Exp Pharmacol Physiol; 2004 Oct; 31(10):704-9. PubMed ID: 15554912
[TBL] [Abstract][Full Text] [Related]
37. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
Pitt B; Bakris G; Ruilope LM; DiCarlo L; Mukherjee R;
Circulation; 2008 Oct; 118(16):1643-50. PubMed ID: 18824643
[TBL] [Abstract][Full Text] [Related]
38. The effects of aldosterone on diet-induced fatty liver formation in male C57BL/6 mice: comparison of adrenalectomy and mineralocorticoid receptor blocker.
Gamliel-Lazarovich A; Raz-Pasteur A; Coleman R; Keidar S
Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1086-92. PubMed ID: 23524523
[TBL] [Abstract][Full Text] [Related]
39. Direct effects of aldosterone on cardiomyocytes in the presence of normal and elevated extracellular sodium.
Yamamuro M; Yoshimura M; Nakayama M; Abe K; Shono M; Suzuki S; Sakamoto T; Saito Y; Nakao K; Yasue H; Ogawa H
Endocrinology; 2006 Mar; 147(3):1314-21. PubMed ID: 16373419
[TBL] [Abstract][Full Text] [Related]
40. Effect of a selective aldosterone receptor antagonist in myocardial infarction.
Delyani JA; Robinson EL; Rudolph AE
Am J Physiol Heart Circ Physiol; 2001 Aug; 281(2):H647-54. PubMed ID: 11454568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
